Sexual Health Stack

PT-141 (Bremelanotide) is the primary peptide studied for sexual function research. FDA-approved as Vyleesi for hypoactive sexual desire disorder, it activates melanocortin-4 receptors in the CNS to modulate arousal pathways — a fundamentally different mechanism from PDE5 inhibitors like sildenafil.

Sexual Health1 compounds14 vendors comparedStack from $320.00

Compounds in this stack

PT-141

PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally in the brain rather than peripherally on the vascular system.

Profile All prices

Role: MC4R agonist (Bremelanotide/Vyleesi). Activates melanocortin-4 receptors in the hypothalamus to promote sexual arousal through central nervous system signaling, not peripheral vasodilation.

1.75mgSubQas needed

1.Peptide Partners100mg

$3.20/mgBuy

2.Peptide Crafters10mg

$3.50/mgBuy

3.Nova Peptides10mg

$4.00/mgBuy

4.Peptidology10mg

$4.30/mgBuy

Bremelanotide for the treatment of hypoactive sexual desire … (2019)Bremelanotide: First Approval (2019)Melanocortin receptor agonists in the treatment of sexual dy… (2007)

Build this stack as a protocol

Use the protocol builder to set doses, frequency, and cycle length. Track your progress with blood work integration.

Start Protocol

Other stacks

Healing & Recovery Stack

The classic tissue repair trinity

Fat Loss Stack

GLP agonist + targeted fat metabolism

Growth Hormone Stack

Synergistic GHRH + GHRP for pulsatile GH release

For research purposes only. Not medical advice, diagnosis, or treatment. Consult a licensed provider before making any decisions based on this information.